Background. Despite the introduction of anti-D prophylaxis into clinical practice, RhD alloimmunization still presents a problem to date. The actual incidence of RhD alloimmunization in pregnant women remains unknown in most countries. Anti-D immunoglobulin is administered to RhD negative women at a fixed dose and in much greater amounts than is actually necessary. On the other hand, it is not possible to diagnose cases where greater doses are needed. To optimize the prevention of RhD alloimmunization in RhD negative women, it is important to diagnose conditions that lead to fetomaternal hemorrhage (FMH), precisely determine the volume and subsequently administer the appropriate dose of anti-D immunoglobulin. The possibility to accurately detect FMH and precisely determine its volume would enable more effective and less costly prevention of RhD alloimmunization. Anti-D immunoglobulin could be administered only in indicated cases and only in doses essentially necessary for prevention of RhD alloimmunization.
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Methods and results. The Cochrane and UpToDate databases of systematic reviews, as well as national guidelines, were reviewed.
Conclusions. Due to the medical significance and indispensable economic costs associated with prevention of RhD alloimmunization, it would be appropriate to establish exact methodical guidelines. The text itself should be limited to a list of potentially sensitising events during which anti-D immunoglobulin should be administered to RhD negative women if anti-D antibodies are not already present. Following each potentially sensitising event, the minimal dose of anti-D immunoglobulin necessary for prevention of RhD alloimmunization should be determined. After 20 weeks of gestation, the volume of FMH should also be determined to specify the necessary dose of anti-D immunoglobulin.
MATERNAL RhD ALLOIMMUNIZATION
Each person who lacks the red blood cell antigen and is exposed to it will create an antibody. During penetration of RhD positive fetal erythrocytes into the circulation of an RhD negative mother, the immune system may be stimulated and trigger the creation of antibodies by "alloimmunization". The same immune reaction may also occur during transfusion of antigen-incompatible erythrocytes.
Anti-D antibodies may cause a severe form of haemolytic disease of the fetus and newborn (HDFNHaemolytic disease of the fetus and newborn). Because the RhD antigen is very potent, even parenteral administration of only 0.1 ml of RhD positive erythrocytes to RhD negative individuals will stimulate the production of antibodies. The most common cause of RhD alloimmunization is hemorrhage, during which fetal erythrocytes enter the mother's circulation.
Most cases of RhD alloimmunization however may theoretically be avoided by prophylactic administration of anti-D immunoglobulin in the necessary dose after every potentially sensitising event (Table 1) .
THE INCIDENCE OF RhD INCOMPATIBLE PREGNANCIES
The incidence of RhD incompatibility varies according to race and ethnic background. Approximately 15% of the Caucasian population is RhD negative. In most other populations however, the incidence of an RhD negative phenotype is significantly lower, in African-Americans the incidence is 5-8%, in Asians and Native Americans 1-2%. In the Caucasian population, an RhD negative woman has an 85% probability that her partner will be RhD positive, in 60% heterozygous and in 40% homozygous at locus RHD. In approximately 10% of all pregnancies, the situation arises where an RhD negative mother will have an RhD positive child and approximately 60% of RhD negative women will have an RhD positive child in their first pregnancy.
In At the beginning of every pregnancy, the woman's AB0 + RhD blood types are determined and screening for irregular anti-erythrocyte antibodies (from herein referred to only as "anti-erythrocyte antibodies") is performed. In the absence of anti-erythrocyte antibodies at the beginning of pregnancy, a follow-up antibody screening is performed at 28 weeks of gestation in all pregnant women (RhD negative and RhD positive). In RhD negative women it is performed before antenatal prophylaxis of RhD alloimmunization, and in RhD positive women it is performed due to the possible development of other than anti-D antibodies causing severe haemolytic disease of the newborn.
If [9] [10] . In the 1 st trimester, women who are RhD negative are administered 50 μg IgG anti-D after spontaneous miscarriage followed by evacuation of the uterus, induced abortion (therapeutic termination of pregnancy), evacuation of the uterus because of mola hydatiforma, chorionic villus sampling or after operation for ectopic pregnancy.
Alloimmunization In the 2 nd and 3 rd trimester, after induced abortion (therapeutic termination of pregnancy), amniocentesis, cordocentesis, or after other invasive prenatal diagnostic or therapeutic procedures, after antepartum hemorrhaging, intrauterine fetal death, attempt at external cephalic version of a breech presentation, after abdominal trauma or in situations where there is a potential risk of sensitization of the mother by RhD antigens of the fetus, a dose of 50 μg of IgG anti-D is administered to RhD negative mothers until 20 weeks of gestation, after 20 weeks of gestation 100 μg of IgG anti-D are administered. After 20 weeks of gestation, the volume of fetomaternal hemorrhage (FMH) should also be determined to specify dosing.
The risk of RhD alloimmunization after amniocentesis is 2-5% (ref. 3 ).
In cases of continued or repeated hemorrhaging after 12 weeks of gestation, 100 μg IgG anti-D are repeatedly administered in 6-week intervals, and during each episode of hemorrhaging the volume of fetomaternal hemorrhage (FMH) should be determined to specify the dose of IgG anti-D necessary for prevention of RhD alloimmunization of the mother [2] [3] [4] [5] . For RhD negative women, after delivery of an RhD positive child, if the presence of anti-D antibodies was not detected in the serum, a 50-100 μg dose of IgG anti-D must be applied intramuscularly and the volume of FMH should be determined to specify the dose of IgG anti-D necessary to prevent RhD alloimmunization of the mother. If the FMH volume is not determined, a dose of 200-300 μg is administered. The effectiveness of administering a standard dose of over 100 μg to all women has not been demonstrated 6, 22 . This dose should be administered immediately following delivery, no later than 72 hours after delivery.
A If the amount of fetal erythrocytes which entered the maternal circulation is quantitatively determined, administration of 10 μg IgG anti-D per 0.5 ml of fetal erythrocytes or 1 ml of whole blood is indicated [6] [7] . In cases where prevention of RhD alloimmunization is not performed within 72 hours of a potentially sensitising event, it is still sensible to administer IgG anti-D within 13 days, and in special cases, administration is still recommended up to a maximum interval of 28 days postpartum 8 . It is necessary to issue a confirming document to women who received IgG anti-D, which precisely describes the amount and form of administration. IgG anti-D should not be administered to women where the presence of anti-D antibodies was confirmed in their blood serum. Exceptions are cases of persisting levels of antenatally administered IgG anti-D. If there is not absolute certainty regarding the origin of anti-D antibodies in the mother's serum, prevention of RhD alloimmunization should be performed. IgG anti-D should also be administered in cases where the RhD status of the child is unknown.
DETERMINING THE VOLUME OF FETOMATERNAL HEMORRHAGE (FMH)
The amount of fetal erythrocytes leaked into the maternal circulation (FMH) is accurately assessed using flow cytometry. After labour, a blood sample from the mother may be drawn no sooner than 1 hour after labour and a sample of 0.5-1.0 ml of venous blood is collected into a test tube containing an anticoagulative substance (EDTA, Heparin).
It is common practise to always examine the RhD status of a child born to an RhD negative woman after labour. Assessing the volume of fetomaternal hemorrhage (FMH) is then indicated in cases, where the child is RhD positive as it allows specification of the dose of IgG anti-D needed for the prevention of RhD alloimmunization of the mother. IgG anti-D is however always administered in a minimally 100 μg dose immediately after detecting a positive RhD status of the child.
Optimal and economically most effective would be to apply a 250 μg dose of anti-D antibody in the 28th week of gestation to RhD-negative women if no anti-D antibodies were detected in their serum. After the birth of an RhD positive child, the volume of fetal erythrocytes which entered maternal circulation should be assessed and only in indicated cases should a dose of IgG anti-D be administered postpartum (Australia) 4 . The volume of fetomaternal hemorrhage (FMH) should also be determined in all RhD negative women where the presence of anti-D antibodies was not determined, in cases of potentially sensitising events (Table 1) after 20 weeks of gestation [5] [6] [7] [20] [21] [22] [23] . The Kleihauer-Betke acid-elution test (UK) or the Rosette test (USA) may be used to roughly determine the volume of fetomaternal hemorrhage.
ESTABLISHING RHD GENOTYPE OF THE FETUS
At the beginning of pregnancy of an RhD negative woman, it is possible to establish the RHD genotype of the fetus from free fetal DNA circulating in maternal peripheral blood. If the fetus is RhD negative, it is unnecessary to administer IgG anti-D at 28 weeks gestation or perform RhD alloimmunization prevention in cases of potentially sensitising events (Table 1) [24] [25] [26] [27] .
